New study demonstrates efficacy of CBD delivery system

April 20, 2020

The extract formulated with VESIsorb saw 4.4-fold higher CBD plasma values, 2.85-fold higher bioavailability eight hours after consumption, and significantly faster absorption. 

A recently published study1 compared the pharmacokinetic parameters of a broad-spectrum hemp extract formulated with a novel self-emulsifying drug delivery system called VESIsorb, produced by Geocann (Fort Collins, CO), to the same extract diluted with medium-chain triglycerides (MCT). Compared to the extract formulated with MCT, subjects taking the extract formulated with VESIsorb saw 4.4-fold higher CBD plasma values, 2.85-fold higher bioavailability eight hours after consumption, and significantly faster absorption at one hour, compared to three hours for the hemp extract in MCT.

“It is well-known that CBD and cannabinoids, in general, show limited bioavailability due to their lipophilicity and extensive first-pass metabolism,” said Marc Weder, chief scientific officer, in a press release. “The results of our study demonstrate VESIsorb technology mitigated this effect and also significantly improved PK performance compared to standard industry practices of combining MCT oil with broad spectrum hemp extract in an effort to improve bioavailability.”

“As our unmatched IP portfolio and body of supporting scientific evidence continues to expand, we are grateful for the peerless reputation the company is receiving in the global marketplace,” added Jesse Lopez, CEO and founder, in a press release. “Most importantly, Geocann is proud of the support we provide to the leading brands we serve, and nothing gives a brand a better advantage than a peer-reviewed published study showing their products work better than competitive offerings.”

References:

1. Knaub K. et al. “A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb® Formulation Technology Improving the Oral Bioavailability of Cannabidiol in Healthy Subjects.” Molecules, vol. 24 (2019): 2967